Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 Combination Therapy in Advanced Malignancies
NCT06468098Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IBI363 in malignant neoplasms (advanced stage), non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 5 more, sponsored by Innovent Biologics. Primary endpoints: Adverse Event, Treatment-Emergent Adverse Event and 8 more. Started Jun 2024; status: recruiting.
02
Drugs
IBI363
03
Conditions
malignant neoplasms (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)biliary tract cancer (BTC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06468098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468098.